StockData
Beta Bionics, Inc. logo

Beta Bionics, Inc. (BBNX) stock

BBNXNasdaqSurgical & Medical Instruments & ApparatusFiscal year ends December 31
Financials through Q3 FY2026, quarter ended Sep 30, 2026Last filing: 10-Q on Oct 27, 2026Score 11/304% below fair value
$14.72−0.49 (-3.22%)

Close on Nov 17, 2026Market cap $800.28MP/E –Yield –

Earnings

Beta Bionics's quarterly results as reported in its earnings releases, with the company's own outlook. Hover a number to see the sentence it came from.

Next report
Feb 16, 2027
Q4 FY2026 · estimated, after the close
Revenue, Q3 FY2026
$35.50M
+30.0% on a year earlier
EPS, Q3 FY2026
-$0.52
Latest guidance
Raised
Oct 27, 2026 · 3 items

Quarterly results

Revenue and earnings per share from each of Beta Bionics's earnings releases, newest first

QuarterReportedRevenueYoYEPSSource
Q4 FY2026ended Dec 31, 2026Feb 16, 2027Expected––––
Q3 FY2026ended Sep 30, 2026Oct 27, 2026after the close$35.50M+30.0%-$0.52Release
Q2 FY2026ended Jun 30, 2026Jul 29, 2026after the close$32.00M+37.9%–Release
Q1 FY2026ended Mar 31, 2026Apr 21, 2026after the close$27.60M+56.8%–Release
Q4 FY2025ended Dec 31, 2025Feb 17, 2026after the close$32.10M+57.4%-$0.30Release
Q3 FY2025ended Sep 30, 2025Oct 28, 2025after the close$27.30M––Release
Q2 FY2025ended Jun 30, 2025Jul 29, 2025after the close$23.20M––Release
Q1 FY2025ended Mar 31, 2025May 6, 2025after the close$17.60M––Release
Q4 FY2024ended Dec 31, 2024Mar 25, 2025after the close$20.40M––Release

Figures as first announced; later restatements appear under Financials. Expected dates are estimated from the company's past reporting pattern.

Current guidance

Beta Bionics's latest outlook for periods it has not reported yet, compared with what it said before

MetricPeriodGuidanceBeforeChangeGiven
total revenueFY2026$124.00M – $126.00M$130.00M – $135.00MLoweredOct 27, 2026
total revenueFY2026$131.00M – $136.00M$131.00M – $136.00MReaffirmedJul 29, 2026
gross marginFY202658.5% – 59.5%55.5% – 57.5%RaisedOct 27, 2026
gross marginFY202658.5% – 59.5%57.5% – 59.5%RaisedJul 29, 2026
new patient starts reimbursed through the PBP channelFY202637% – 39%36% – 38%RaisedOct 27, 2026
new patient starts reimbursed through the PBP channelFY202637% – 39%37% – 39%ReaffirmedJul 29, 2026

Guidance vs results

The last range Beta Bionics gave before each report, against the figure it then reported. Full years add up the four quarters.

PeriodMetricGuidanceActualResult
FY2025Revenue$96.50M$100.20MΣ4QAbove range

Guidance history

Every forecast Beta Bionics put in an earnings release, newest first

GivenMetricPeriodGuidanceChange
Oct 27, 2026gross marginFY202658.5% – 59.5%Raised
Oct 27, 2026new patient starts reimbursed through the PBP channelFY202637% – 39%Raised
Oct 27, 2026total revenueFY2026$124.00M – $126.00MLowered
Jul 29, 2026gross marginFY202658.5% – 59.5%Raised
Jul 29, 2026new patient starts reimbursed through the PBP channelFY202637% – 39%Reaffirmed
Jul 29, 2026total revenueFY2026$131.00M – $136.00MReaffirmed
Apr 21, 2026gross marginFY202657.5% – 59.5%New
Apr 21, 2026new patient starts reimbursed through the PBP channelFY202637% – 39%New
Apr 21, 2026total revenueFY2026$131.00M – $136.00MNew
Feb 17, 2026gross marginFY202655.5% – 57.5%New
Feb 17, 2026new patient starts reimbursed through the PBP channelFY202636% – 38%New
Feb 17, 2026total revenueFY2026$130.00M – $135.00MNew
Oct 28, 2025gross marginFY202554% – 55%New
Oct 28, 2025new patient starts reimbursed through the PBP channelFY202527% – 29%New
Oct 28, 2025total revenueFY2025$96.50MNew
Jul 29, 2025gross marginFY202552% – 55%Raised
Jul 29, 2025percentage of new patient starts reimbursed through the PBP channelFY202525% – 28%Raised
Jul 29, 2025total revenueFY2025$88.00M – $93.00MRaised
May 6, 2025gross marginFY202550% – 53%Raised
May 6, 2025percentage of new patient starts reimbursed through the PBP channelFY202522% – 25%Raised

Read from the company's earnings releases; each figure links to its sentence on hover. “Raised” and “Lowered” compare with the previous range for the same metric and period.

Press releases

Releases Beta Bionics filed with the SEC as exhibits to Form 8-K or 6-K

  1. Results
  2. News
  3. News
  4. Update
  5. Update
  6. Results
  7. Update
  8. Results
  9. Results
  10. Results
  11. Results
  12. Results
  13. Update
  14. Results
  15. Results

See a number that looks wrong?